AB Science: New Peer-Reviewed Masitinib Trial Shows Strong Evidence Supporting Potential To Treat AD

French pharmaceutical firm AB Science SA announced new peer-reviewed data from an independent Chinese study supporting its drug Masitinib's potential for sporadic Alzheimer's disease (sAD), which comprises over 95% of cases. The research highlights Masitinib's dual mechanism of cognitive enhancement and neuroprotection by targeting the brain's innate immune system and reducing toxic proteins. This new evidence complements prior clinical data, with AB Science already holding FDA IND approval and European authorizations for a Phase III study (AB21004) designed to confirm positive results from a previous Phase 2B/3 trial. The company has also filed a patent application that could secure intellectual property protection for Masitinib in this indication until 2041, underscoring its potential as a significant therapeutic candidate.

Analysis

AB Science SA has received a significant external validation for its lead drug, Masitinib, as a potential treatment for sporadic Alzheimer's disease (sAD), which constitutes over 95% of cases. A new, independent peer-reviewed study from Chinese universities reinforces the drug's dual mechanism of cognitive enhancement and neuroprotection. This research highlights Masitinib's differentiated approach, which targets the brain's innate immune system—specifically mast cells and microglia—and reduces toxic proteins like hyperphosphorylated Tau while protecting synapses. This external corroboration strengthens the scientific foundation ahead of a pivotal regulatory milestone. The company has already secured Investigational New Drug (IND) approval from the FDA and European authorizations to initiate a confirmatory Phase III study (AB21004). This trial is designed to replicate positive data from a prior Phase 2B/3 study (AB09004), which demonstrated a significant slowing of cognitive and functional decline. Furthermore, AB Science has proactively filed a patent application which, if granted, would secure intellectual property protection for Masitinib in this indication until 2041, underpinning the drug's long-term commercial potential in a market with substantial unmet need.

Key Decisions for Investors

• The positive, independent data should be viewed as a material de-risking event for Masitinib's clinical pathway, potentially increasing its probability of success and warranting a re-evaluation of its potential in the high-value Alzheimer's market.
• Investors should focus on the progress and eventual data readout from the confirmatory Phase III study (AB21004), as this remains the primary binary catalyst that will determine the drug's approvability and ultimate value.
• The new patent application, aiming to extend intellectual property protection to 2041, significantly enhances the long-term commercial thesis and should be factored into valuation models, contingent on clinical success.